"Cytochrome P-450 CYP3A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P-450 suptype that has specificity for a broad variety of lipophilic compounds, including STEROIDS; FATTY ACIDS; and XENOBIOTICS. This enzyme has clinical significance due to its ability to metabolize a diverse array of clinically important drugs such as CYCLOSPORINE; VERAPAMIL; and MIDAZOLAM. This enzyme also catalyzes the N-demethylation of ERYTHROMYCIN.
| Descriptor ID |
D051544
|
| MeSH Number(s) |
D08.244.453.860.500 D08.811.682.662.582.353 D08.811.682.690.708.170.495.500 D12.776.422.220.453.860.500
|
| Concept/Terms |
Cytochrome P-450 CYP3A- Cytochrome P-450 CYP3A
- Cytochrome P 450 CYP3A
- P-450 CYP3A, Cytochrome
- Cytochrome P-450IIIA
- Cytochrome P 450IIIA
- P-450IIIA, Cytochrome
- Erythromycin N-Demethylase
- Erythromycin N Demethylase
- N-Demethylase, Erythromycin
- CYP3A
- Cytochrome P450 3A
- P450 3A, Cytochrome
Cytochrome P-450 CYP3A5- Cytochrome P-450 CYP3A5
- Cytochrome P 450 CYP3A5
- P-450 CYP3A5, Cytochrome
- CYP3A5
- Cytochrome P450 3A5
- 3A5, Cytochrome P450
- P450 3A5, Cytochrome
Cytochrome P-450 CYP3A4- Cytochrome P-450 CYP3A4
- Cytochrome P 450 CYP3A4
- P-450 CYP3A4, Cytochrome
- Cytochrome P450 3A4
- Taurochenodeoxycholate 6-alpha-Monooxygenase
- 6-alpha-Monooxygenase, Taurochenodeoxycholate
- Taurochenodeoxycholate 6 alpha Monooxygenase
- CYP3A4
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP3A".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP3A".
This graph shows the total number of publications written about "Cytochrome P-450 CYP3A" by people in this website by year, and whether "Cytochrome P-450 CYP3A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 2 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytochrome P-450 CYP3A" by people in Profiles.
-
Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation. Pharmacogenet Genomics. 2023 04 01; 33(3):59-65.
-
Select drug-drug interactions with colchicine and cardiovascular medications: A review. Am Heart J. 2022 10; 252:42-50.
-
Population pharmacokinetics of sildenafil in extremely premature infants. Br J Clin Pharmacol. 2019 12; 85(12):2824-2837.
-
Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study. Pharmacogenet Genomics. 2018 08; 28(8):189-195.
-
Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther. 2012 May; 91(5):881-8.
-
Potentiation of vincristine toxicity with concomitant fluconazole prophylaxis in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2012 Feb; 29(1):62-7.
-
Biological effects of marine contaminated sediments on Sparus aurata juveniles. Aquat Toxicol. 2011 Aug; 104(3-4):308-16.
-
Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat. 2011 May; 127(1):153-62.
-
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Clin Pharmacol Ther. 2008 Jul; 84(1):111-8.
-
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006 May; 57(5):685-92.